NCT03413176View on ClinicalTrials.gov

Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.

CompletedOBSERVATIONAL

Enrollment

150,000

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

January 15, 2018

Study Completion Date

January 31, 2018

Conditions

Cardiac ComplicationVascular Diseases

Interventions

DRUG

Cardiac complication induced by VEGF/VEGFR inhibitor

Case reported in the World Health Organization (WHO) of cardiac complication of patient treated by AAs, with a chronology compatible with the drug toxicity

Trial Locations (1)

75013

AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM., Paris

All Listed Sponsors

lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT03413176 - Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN. | Biotech Hunter | Biotech Hunter